Antiviral Agents in Development for Zika Virus Infections
AbstractIn 1947, Zika virus (ZIKV), a mosquito-borne flavivirus was identified in Uganda and subsequently spread to Asia and the Pacific regions. In 2015, it was introduced in Brazil causing an important social and sanitary alarm due to its increased virulence and rapid dissemination. Importantly, ZIKV infections have been associated with severe neurological complications such as Guillain–Barré syndrome and microcephaly in fetuses and newborns. Although enormous efforts were made by investigators in the development of effective countermeasures against ZIKV, there is still no approved specific antiviral drug for the treatment of ZIKV infections. Herein, we review several anti ZIKV candidates including drugs targeting both the virus (structural proteins and enzymes) and cellular elements. View Full-Text
Share & Cite This Article
Baz, M.; Boivin, G. Antiviral Agents in Development for Zika Virus Infections. Pharmaceuticals 2019, 12, 101.
Baz M, Boivin G. Antiviral Agents in Development for Zika Virus Infections. Pharmaceuticals. 2019; 12(3):101.Chicago/Turabian Style
Baz, Mariana; Boivin, Guy. 2019. "Antiviral Agents in Development for Zika Virus Infections." Pharmaceuticals 12, no. 3: 101.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.